CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT IMMUNOCORE TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 1 TO SIDE LETTERImmunocore Holdings PLC • May 28th, 2024 • Biological products, (no disgnostic substances)
This AMENDMENT NO. 1 TO SIDE LETTER (the “Amendment”) dated as of February 6, 2024, is made with reference to the Letter Agreement dated January 21, 2021 (the “Side Letter”) by and between IMMUNOCORE HOLDINGS LIMITED, 667, L.P., and BAKER BROTHERS LIFE SCIENCES, L.P. (collectively, the “Parties”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 28th, 2024 • Immunocore Holdings PLC • Biological products, (no disgnostic substances) • New York
This Registration Rights Agreement (this “Agreement”) is made as of May 28, 2024 by and between Immunocore Holdings plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
